坎伯兰药业 2026年季度报告

Cumberland Pharmaceuticals Inc. Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)has been Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of"large accelerated filer,""accelerated filer,""smaller reporting company" If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant toSection 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 14,983,107 sharesof common stock as of May5, 2026. PART I – FINANCIAL INFORMATIONItem1. Financial Statements (Unaudited)Condensed Consolidated Balance SheetsCondensed Consolidated Statements of OperationsCondensed Consolidated Statements of Cash FlowsCondensed Consolidated Statements of EquityNotes to the Condensed Consolidated Financial StatementsItem2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem3. Quantitative and Qualitative Disclosures About Market RiskItem4. Controls and ProceduresPART II – OTHER INFORMATIONItem1. Legal ProceedingsItem1A. Risk FactorsItem2. Unregistered Sales of Equity Securities and Use of ProceedsItem 5. Other InformationItem6. Exhibits 1 1 SIGNATURES PART I – FINANCIAL INFORMATION CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIESNotes to Condensed Consolidated Financial Statements (1) ORGANIZATION AND BASIS OF PRESENTATION Cumberland Pharmaceuticals Inc. ("Cumberland," the "Company," or as used in the context of "we," "us," or "our"), is a specialtypharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceuticals. We Our primary target markets are hospital acute care, gastroenterology and oncology. These medical specialties are characterized byrelatively concentrated prescriber bases that we believe can be served effectively by small, targeted sales forces. We promote ourapproved products through our hospital, field and oncology sales forces in the United States. We continue to build a network of Cumberland’s growth strategy involves maximizing the potential of our existing brands, while continuing to build a portfolio ofdifferentiated products. Our current portfolio includes seven products approved by the U.S. Food and Drug Administration ("FDA") inthe United States. We also continue to build international partnerships to bring our medicines to patients in other countries.Additionally, we look for opportunities to expand our brands into new patient populations through clinical trials, new productpresentations and our support of select, investigator-initiated studies. Meanwhile, our clinical team is developing a pipeline of new The Company’s products are manufactured by third parties, which are overseen by our quality control and manufacturingprofessionals. We work closely with our warehousing and distribution partners to make our products available in the U.S. In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have beenprepared on a basis consistent with the December 31, 2025, audited consolidated financial statements and include all adjustments,consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significantintercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financialstatements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the "SEC"), andcertain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These Recent Accounting Guidance Recent Accounting Pronouncements In November 2023, the Financial Accounting Standards Board ("FASB") issued final guidance in Accounting Standards Update("ASU") 2023-07,Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,which is intended to improvetransparency of segment disclosures, primarily through expanded disclosures for significant segment expenses. The guidance iseffective for